mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers

The interplay of ROS and the PI3K/Akt pathway in autophagy regulation

(2021) Dr Lakhan Kma et al.   BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY

MIEF2 reprograms lipid metabolism to drive progression of ovarian cancer through ROS/AKT/mTOR signaling pathway

(2021) Shuhua Zhao et al.   Cell Death & Disease

Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients

(2021) Xi Chen et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients

(2021) Angelika M Starzer et al.   Journal for ImmunoTherapy of Cancer

mTOR pathway and DNA damage response: A therapeutic strategy in cancer therapy

(2021) Romina Danesh Pazhooh et al.   DNA REPAIR

Identification of deleterious NOTCH mutation as novel predictor to efficacious immunotherapy in NSCLC

(2020) Kai Zhang et al.   CLINICAL CANCER RESEARCH

Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial

(2020) Akihito Kawazoe et al.   LANCET ONCOLOGY

Genome and transcriptome biomarkers of response to immune checkpoint inhibitors in advanced solid tumours

(2020) Alexandra Pender et al.   CLINICAL CANCER RESEARCH

mTOR Signaling in Metabolism and Cancer

(2020) Shile Huang   Cells

Identification of molecular features correlating with tumor immunity in gastric cancer by multi-omics data analysis

(2020) Yin He et al.   Annals of Translational Medicine

Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors

(2020) Lei Zhang et al.   JAMA Network Open

Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

(2020) Thierry André et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

(2019) Robert M. Samstein et al.   NATURE GENETICS

Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer

(2019) Edith Borcoman et al.   OncoImmunology

Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma

(2019) Junfei Zhao et al.   NATURE MEDICINE

Targeting Immune Checkpoints in Lung Cancer: Current Landscape and Future Prospects

(2019) Long Long et al.   CLINICAL DRUG INVESTIGATION

Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non‐small cell lung cancer

(2019) Ilaria Alborelli et al.   JOURNAL OF PATHOLOGY

The Immune Landscape of Cancer

(2018) Vésteinn Thorsson et al.   IMMUNITY

MICAL1 facilitates breast cancer cell proliferation via ROS-sensitive ERK/cyclin D pathway

(2018) Wenjie Deng et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression

(2018) Heng Lin et al.   JOURNAL OF CLINICAL INVESTIGATION

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

(2018) Patrick M. Forde et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma

(2018) Diana Miao et al.   SCIENCE

ROS signalling in the biology of cancer

(2018) Jennifer N. Moloney et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

(2018) Sanjeev Mariathasan et al.   NATURE

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

(2018) David R. Gandara et al.   NATURE MEDICINE

Altered cancer metabolism in mechanisms of immunotherapy resistance

(2018) Rishab Ramapriyan et al.   PHARMACOLOGY & THERAPEUTICS

Bioassay of saliva proteins: The best alternative for conventional methods in non-invasive diagnosis of cancer

(2018) Aziz Eftekhari et al.   INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Antioxidants in the Treatment of Cancer

(2017) Kanthi Athreya et al.   NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

(2016) Willy Hugo et al.   CELL

Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer

(2015) Kristin J. Lastwika et al.   CANCER RESEARCH

Oxidized ATM promotes abnormal proliferation of breast CAFs through maintaining intracellular redox homeostasis and activating the PI3K-AKT, MEK-ERK, and Wnt-β-catenin signaling pathways

(2015) Shifu Tang et al.   CELL CYCLE

mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer

(2015) W. Mo et al.   CLINICAL CANCER RESEARCH

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

(2015) E. M. Van Allen et al.   SCIENCE

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

mTOR, linking metabolism and immunity

(2013) Xiaojin Xu et al.   SEMINARS IN IMMUNOLOGY

The Transcription Factor Myc Controls Metabolic Reprogramming upon T Lymphocyte Activation

(2011) Ruoning Wang et al.   IMMUNITY

The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2

(2011) Greg M Delgoffe et al.   NATURE IMMUNOLOGY

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Activation of a Metabolic Gene Regulatory Network Downstream of mTOR Complex 1

(2010) Katrin Düvel et al.   MOLECULAR CELL

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

The mTOR Kinase Differentially Regulates Effector and Regulatory T Cell Lineage Commitment

(2009) Greg M. Delgoffe et al.   IMMUNITY